All In Biotech

Drug Trial Radar · NCT05180734

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy Versus Placebo Combined With Postoperative Adjuvant Chemotherapy in Patients With Gastric or Esophagogastric Junction Adenocarcinoma After Radical Gastrectomy

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 878 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

878

Actual

Start

Feb 10, 2022

Primary completion

Mar 31, 2027

Study completion Jul 31, 2028

Sponsor

Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage IIB or III (AJCC Cancer Staging Manual, 8th Edition) gastric or EGJ adenocarcinoma to evaluate the efficacy and safety of JS001 combined with postoperative adjuvant chemotherapy versus placebo combined with postoperative adjuvant chemotherapy.

Conditions

  • Gastric or Esophagogastric Junction Adenocarcinoma

Interventions

  • JS001/PlaceboBiological

    JS001/placebo combine with Postoperative Adjuvant Chemotherapy

  • JS001/placebo combine with Postoperative Adjuvant ChemotherapyBiological

    JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DFS in the PD-L1-positive population evaluated by the BICRTime frame: 5 years

Locations

71 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The Peple's Hospital of Chizhou

    Chizhou, Anhui, China

  • Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Peking University People's hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China

  • The first affiliated hospital of chongqing medical universit

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • The first Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Wuwei Cancer Hospital of Gansu Province

    Wuwei, Gansu, China

  • Guandong General Hospital

    Guangzhou, Guandong, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guandong, China

  • The First People's Hospital of Foshan

    Foshan, Guangdong, China

  • The First Affiliated Hospital of Sun yat-sen University

    Guangzhou, Guangdong, China

  • Affiliated Cancer Hospital and Institute of Ghuangzhou Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The 2ed Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of science and Technology

    Luoyang, Henan, China

  • Henan cancer hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hopital

    Changsha, Hunan, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Jiangsu cancer hospital

    Nanjing, Jiangsu, China

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.